List of Excipients in Branded Drug FERUMOXYTOL

Generic Drugs Containing FERUMOXYTOL

Company	Ingredient	NDC	Excipient
Sandoz Inc	ferumoxytol	0781-3154	MANNITOL

What are the Most Frequently-Used Excipients in FERUMOXYTOL?

# Of NDCs	Excipient
1	MANNITOL

Ferumoxytol Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Ferumoxytol is an intravenous iron-carbohydrate nanoparticle marketed in the United States as Feraheme by AMAG Pharmaceuticals, now part of Covis Pharma. Its core commercial value is the ability to deliver 510 mg of elemental iron per 17 mL dose, usually in two administrations separated by three to eight days. The principal excipient opportunity is not a conventional tablet or injectable vehicle strategy. It is the controlled design of the iron-carbohydrate complex, particle surface, colloidal stability, infusion presentation, and manufacturing process.

The highest-value opportunities are improved infusion safety, ready-to-use presentations, lower administration burden, global product adaptation, generic or complex-generic development, and next-generation iron nanoparticles. The principal barriers are the product’s complex physicochemical structure, hypersensitivity risk, intravenous administration requirements, and the difficulty of demonstrating equivalence to the reference product.

What is the ferumoxytol formulation and which excipients does it contain?

Ferumoxytol is an iron oxide nanoparticle coated with polyglucose sorbitol carboxymethylether. The coating controls particle dispersion, iron release, pharmacokinetics, and interaction with biological systems. Feraheme injection contains 30 mg of elemental iron per mL in an intravenous formulation. The U.S. prescribing information identifies mannitol and water for injection as inactive ingredients; the iron oxide and carbohydrate coating are part of the active iron-carbohydrate complex rather than conventional excipients.[1]

Formulation attribute	Feraheme characteristic
Active ingredient	Ferumoxytol
Iron concentration	30 mg elemental iron/mL
Dose	510 mg elemental iron per administration
Nominal dose volume	17 mL
Route	Intravenous infusion
Primary colloidal component	Iron oxide nanoparticle
Surface coating	Polyglucose sorbitol carboxymethylether
Listed inactive ingredients	Mannitol and water for injection
Administration	Diluted in 50-200 mL of 0.9% sodium chloride or 5% dextrose and infused over at least 15 minutes
Key safety issue	Serious hypersensitivity, including anaphylaxis

The coating is commercially more important than the simple solution excipients. Changes to the carbohydrate shell, particle size distribution, surface charge, iron-core crystallinity, aggregation profile, or free-iron content can alter clinical performance and regulatory comparability.

What excipient functions are most important in ferumoxytol?

Four functions determine the commercial and regulatory performance of the formulation.

Colloidal stabilization

The formulation must prevent aggregation during manufacture, storage, dilution, transport, and infusion. Particle aggregation can change viscosity, filterability, infusion behavior, biodistribution, macrophage uptake, and hypersensitivity risk.

Mannitol may support isotonicity and formulation robustness, but it does not replace the structural role of the carbohydrate coating. A developer seeking a differentiated product would focus on the nanoparticle surface rather than simply substituting mannitol with another tonicity agent.

Control of iron release

The coating must retain the iron oxide core sufficiently to avoid excessive labile iron exposure while permitting physiologic processing by macrophages. A formulation with faster iron release could reduce the time to iron availability but may increase oxidative or infusion-related risks. A formulation with slower release could improve tolerability but reduce the perceived clinical advantage.

Control of hypersensitivity risk

Ferumoxytol carries a boxed warning for serious and potentially fatal hypersensitivity reactions. The label requires administration in a setting with immediate access to personnel and therapies capable of treating anaphylaxis, with observation for at least 30 minutes after each dose.[1]

Excipient and particle-surface changes could influence complement activation-related pseudoallergy, macrophage interaction, protein adsorption, and infusion reactions. A product claim based on lower reaction rates would require substantial clinical evidence and would be difficult to support through formulation data alone.

Manufacturing reproducibility

The critical quality attributes include:

• Iron content and elemental iron assay
• Particle size and size distribution
• Iron-core morphology and crystallinity
• Surface-coating identity and density
• Free or labile iron
• Zeta potential and colloidal stability
• Osmolality and pH
• Viscosity
• Subvisible and visible particles
• Endotoxin and sterility
• Dilution stability
• Container-closure compatibility

For complex iron products, batch-to-batch control of these attributes is central to regulatory acceptance. FDA has treated iron-carbohydrate products as complex products for which sameness cannot be established solely through conventional small-molecule analytical testing.[2]

What formulation patents could protect ferumoxytol products?

Patent protection for ferumoxytol can extend beyond the named active ingredient. The most relevant claim categories are the following:

Patent category	Potential protected subject matter	Commercial relevance
Composition	Iron oxide core with polyglucose sorbitol carboxymethylether coating	Protects the core product architecture
Particle design	Size distribution, coating ratio, surface chemistry, iron oxidation state	May constrain complex-generic design
Manufacturing	Precipitation, coating, purification, concentration, and sterilization processes	Can create supply and CMC barriers
Formulation	Concentration, pH, tonicity, stabilizers, dilution conditions, and container closure	Supports lifecycle management
Method of use	Treatment of iron-deficiency anemia, chronic kidney disease, or oral-iron intolerance	Can affect label carve-outs and litigation
Administration	Infusion duration, dosing intervals, or administration protocols	May support differentiated clinical use
Combination products	Use with dialysis, erythropoiesis-stimulating agents, or specific supportive therapies	Niche commercial protection

The practical patent risk does not depend only on whether a composition patent remains in force. Process patents, manufacturing know-how, analytical methods, and regulatory exclusivity can delay or raise the cost of entry. A generic developer may avoid a patent claim yet still face difficulty reproducing the reference product’s critical quality attributes.

When does ferumoxytol lose exclusivity and what is the generic entry risk?

Feraheme received U.S. approval in 2009. The product’s regulatory exclusivity periods have expired, and the principal commercial question is now the status and scope of any remaining patents, litigation settlements, and approved or pending abbreviated applications.

Ferumoxytol is not a biologic and is not approved through the biosimilar pathway. A competing product would generally require an abbreviated new drug application or another pathway applicable to complex iron products. FDA’s product-specific recommendations and general guidance for iron-carbohydrate complexes make analytical similarity, physicochemical characterization, and clinical or pharmacodynamic evidence central issues.[2,3]

Paragraph IV challenges

A Paragraph IV applicant could challenge listed patents by asserting that they are invalid, unenforceable, or not infringed. The most commercially meaningful challenge would likely target composition or method-of-use claims that block use of a ferumoxytol product in the largest labeled populations.

The risk profile is mixed:

• A conventional ANDA may be less expensive than a full new drug application.
• Demonstrating pharmaceutical equivalence is difficult because ferumoxytol is a nanoparticle complex.
• A Q1/Q2 formulation match may reduce formulation risk but may not establish full equivalence.
• A different coating or particle architecture may avoid patents but trigger additional clinical and CMC requirements.
• Label carve-outs may be possible for method-of-use patents, but they may reduce the commercial addressable market.

Biosimilar risk

Biosimilar risk is low in the formal regulatory sense because ferumoxytol is not a biologic reference product. The more relevant threat is complex-generic or follow-on iron-carbohydrate competition. Such products can have a commercial effect similar to biosimilars by using a lower-price strategy against the reference product.

What excipient strategies could create commercial opportunities?

Ready-to-use and low-handling presentations

Feraheme is diluted before infusion under the U.S. label. A ready-to-use or simplified presentation could reduce pharmacy preparation, dilution errors, waste, and chair time. Potential formats include:

• A pre-diluted infusion bag
• A smaller-volume high-concentration presentation
• A pharmacy-ready vial with validated dilution instructions
• A closed-system transfer presentation
• A device-compatible container for outpatient infusion centers

The commercial value would be highest in nephrology, hospital outpatient departments, and infusion clinics where labor and chair time affect treatment economics.

Improved dilution stability

A differentiated formulation could maintain particle size, iron content, and visual quality after dilution for a defined period. Extended in-use stability could support centralized pharmacy preparation and reduce discarded doses. Such a claim would require validated data for multiple diluents, container materials, storage temperatures, and hold times.

Reduced hypersensitivity potential

A lower-reactogenic formulation would have substantial value, but the evidentiary burden is high. Relevant approaches could include:

• Altering surface-carbohydrate density
• Narrowing particle-size distribution
• Reducing free iron
• Controlling surface charge
• Removing process-related impurities
• Optimizing infusion concentration and rate

A sponsor could pursue this as a new formulation, a new drug product, or a lifecycle-management program. A lower reaction rate would need prospective clinical testing because in vitro complement or cytokine assays would not establish clinical safety.

Pediatric and special-population formulations

Ferumoxytol is commercially concentrated in adult indications. Pediatric development could create a separate opportunity if a suitable dose-volume and administration strategy were established. Potential formulation needs include lower-dose presentations, more precise dose measurement, and validated use in patients with chronic kidney disease or inflammatory conditions.

Pediatric commercialization would require more than an excipient change. Dose selection, developmental pharmacology, safety monitoring, and age-specific administration would be material regulatory requirements.

Global-market adaptation

Feraheme has had a more substantial U.S. commercial presence than international reach. A global formulation program could target markets in which intravenous iron is used broadly but where administration infrastructure differs. Opportunities include:

• Smaller vial sizes for lower initial inventory
• Packaging adapted to local cold-chain and distribution conditions
• Compatibility with common regional infusion containers
• Presentations suitable for dialysis centers
• Manufacturing closer to high-growth markets

Changes to the carbohydrate coating or particle process could trigger a new regulatory comparability exercise in each jurisdiction.

How does ferumoxytol compare with competing intravenous iron products?

Ferumoxytol competes with ferric carboxymaltose, iron sucrose, ferric derisomaltose, and sodium ferric gluconate. Its commercial positioning depends on dose density, number of visits, safety, reimbursement, and institutional protocols.

Product	Typical administration profile	Main commercial strength	Main competitive pressure
Ferumoxytol	Two 510 mg doses, generally 3-8 days apart	High iron dose with relatively few visits	Hypersensitivity warning and complex-generic barriers
Ferric carboxymaltose	Large-dose IV replacement, often one or two administrations	Broad use and established hospital adoption	Hypophosphatemia concerns and price competition
Ferric derisomaltose	High-dose replacement, often one administration	Reduced visit burden	Competes directly on convenience and total treatment cost
Iron sucrose	Multiple smaller doses	Extensive clinical familiarity and generic availability	More visits and administration burden
Sodium ferric gluconate	Fractionated dosing, often dialysis-related	Established dialysis use	Lower dose per visit

The strongest commercial differentiator for ferumoxytol is dose efficiency. That advantage narrows when competitors offer single-visit high-dose treatment or when payers emphasize acquisition cost rather than total treatment cost.

What manufacturing and intellectual-property barriers affect ferumoxytol?

The main manufacturing barrier is process control. The product requires reproducible formation of an iron oxide core and consistent attachment of the carbohydrate coating. Small deviations can affect critical quality attributes and clinical comparability.

Key barriers include:

1. Access to validated iron oxide nanoparticle manufacturing technology.
2. Control of particle-size distribution at commercial scale.
3. Removal of unbound coating and low-molecular-weight impurities.
4. Sterile filtration or aseptic processing without destabilizing the complex.
5. Analytical methods capable of distinguishing meaningful structural differences.
6. Long-term stability data for the finished product.
7. Scale-up without changing surface chemistry or aggregation behavior.
8. Supply of pharmaceutical-grade carbohydrate coating materials.

These barriers can support a durable manufacturing advantage even after basic composition patents expire. A follow-on company may require several years of process development before filing.

What is the FDA regulatory status of Feraheme?

Feraheme is FDA-approved for the treatment of iron-deficiency anemia in adults with chronic kidney disease and for adults who have intolerance to oral iron, have had an unsatisfactory response to oral iron, or have chronic kidney disease.[1] The approved product carries a boxed warning for serious hypersensitivity reactions.

The FDA label requires diluted administration by intravenous infusion over at least 15 minutes, with monitoring during and after administration. The label also includes warnings relating to hypotension, iron overload, and magnetic resonance imaging interference.[1]

The MRI issue has commercial relevance. Ferumoxytol can alter MRI results for a period after administration. A differentiated product with more predictable MRI interference duration, or clearer scheduling guidance, could reduce operational friction in hospitals.

Which licensing and partnership opportunities exist?

Ferumoxytol commercial opportunities are more likely to involve manufacturing, regional commercialization, and complex-generic development than a conventional excipient licensing deal.

Potential transaction structures include:

• Regional rights for Feraheme or a follow-on product
• Contract manufacturing of the iron-carbohydrate complex
• Licensing of nanoparticle coating and characterization technology
• Co-development of a ready-to-use infusion presentation
• Hospital-system partnerships based on reduced administration time
• Supply agreements with dialysis and nephrology networks
• Development partnerships for pediatric or global-market formulations

A technology owner with validated particle characterization and scale-up capability could have greater leverage than a party holding a simple excipient substitution patent. The strongest assets would combine composition claims, manufacturing know-how, analytical methods, and regulatory data.

What revenue exposure and launch scenarios should investors monitor?

The most important commercial variables are net price, payer restrictions, treatment volume, and the timing of complex-generic entry. Three launch scenarios are relevant.

Scenario	Likely market effect	Principal trigger
No near-term follow-on entry	Maintains price and physician familiarity	Continued CMC and patent barriers
One approved follow-on product	Moderate price erosion and formulary pressure	Successful equivalence package
Multiple complex-generic entrants	Rapid price compression and contracting competition	Reproducible manufacturing platform

Revenue exposure is concentrated in adult nephrology, chronic kidney disease, and infusion-center use. A lower-cost competitor would likely first target high-volume institutional accounts, where procurement committees can substitute products more readily than individual outpatient physicians.

A lifecycle product with lower preparation burden or a stronger safety profile could preserve premium pricing. An excipient-only change without a clear operational or clinical advantage is unlikely to support a durable premium.

Key Takeaways

• Ferumoxytol is a complex iron oxide-carbohydrate nanoparticle, not a conventional solution formulation.
• The polyglucose sorbitol carboxymethylether coating is the central formulation and manufacturing component.
• Mannitol and water for injection are listed inactive ingredients in the U.S. Feraheme formulation.
• The most valuable excipient opportunities involve nanoparticle stability, free-iron control, infusion safety, dilution stability, and ready-to-use administration.
• Ferumoxytol faces complex-generic risk rather than formal biosimilar risk.
• Manufacturing reproducibility and analytical comparability may be stronger barriers than basic composition patent protection.
• High-value lifecycle opportunities include pre-diluted infusion products, lower-volume administration, pediatric presentations, and formulations designed to reduce hypersensitivity risk.
• Competitive pressure comes from ferric carboxymaltose, ferric derisomaltose, iron sucrose, and sodium ferric gluconate.
• Any premium formulation strategy must produce a measurable reduction in treatment burden, preparation cost, safety risk, or total infusion-center cost.

FAQs About Ferumoxytol Excipient Strategy

Can mannitol be replaced in a ferumoxytol formulation?

Potentially, but substitution would require evaluation of osmolality, viscosity, particle stability, infusion tolerability, container compatibility, and product comparability. Mannitol is not the primary structural stabilizer of the iron-carbohydrate nanoparticle.

Is ferumoxytol eligible for a biosimilar application?

No. Ferumoxytol is not a biologic reference product. A competitor would more likely pursue an ANDA or another applicable pathway for a complex iron-carbohydrate product.

What is the most commercially valuable ferumoxytol formulation improvement?

A validated ready-to-use or pharmacy-ready presentation with extended dilution stability could deliver immediate operational value. A formulation with clinically demonstrated lower hypersensitivity risk would have greater strategic value but a substantially higher development burden.

Can a ferumoxytol generic use a different carbohydrate coating?

A different coating may avoid specific composition claims, but it could produce a materially different product. That difference may require additional clinical, pharmacologic, and regulatory evidence rather than a straightforward generic showing.

Does ferumoxytol compete mainly on price or dosing convenience?

Its original commercial positioning relied heavily on high-dose iron delivery with relatively few administrations. As other products offer similarly high-dose or single-visit treatment, price, formulary placement, safety perception, and infusion-center economics become more important.

References

1. U.S. Food and Drug Administration. (2022). Feraheme (ferumoxytol injection) prescribing information. AMAG Pharmaceuticals/Covis Pharma.

2. U.S. Food and Drug Administration. (2020). Evaluation of therapeutic equivalence for complex drug products: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2016). Drug products, including biological products, that contain nanomaterials: Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2023). Feraheme drug approval package and labeling materials. U.S. Department of Health and Human Services.